Robert Heimer, PhD

Professor of Epidemiology (Microbial Diseases) and of Pharmacology; Director, Emerging Infections Program

Research Interests

Acquired Immunodeficiency Syndrome; Epidemiology; Foodborne Diseases; Hepatitis C; Injections; Public Health; Russia; Vietnam; Global Health; HIV Infections

Public Health Interests

Drug Abuse/Addition; HIV/AIDS

Research Summary

Dr. Heimer is also the Director of the Yale office of the Connecticut Emerging Infections Program. This Centers for Disease Control and Prevention-funded program is one of eleven programs nationwide that seek to assess, through population-based surveillance, the public health impact of emerging infectious diseases and to evaluate methods for their prevention and control in the community. The Yale program currently focuses on chronic liver disease (especially hepatitis C), foodborne illnesses, and respiratory illnesses.

Dr. Heimer's major research efforts include scientific investigation of the mortality and morbidity associated with injection drug use. Areas of investigation include syringe exchange programs, HIV survival in syringes, hepatitis B vaccination, hepatitis C transmission risks, overdose prevention and resuscitation, and pharmacological treatment of opiate addiction. His research combines laboratory, operational, and ethnographic analyses to evaluate the effectiveness of intervention programs in preventing the negative medical consequences of injection drug use. Dr. Heimer is Director of the Interdisciplinary Research Methods Core at Yale's Center for Interdisciplinary Research on AIDS.

Specialized Terms: Mortality and morbidity in relation to injection drug use; HIV and hepatitis C transmission; Evaluation of prevention and treatment for people who inject drugs

Extensive Research Description

Robert Heimer is a professor of epidemiology and public health and pharmacology at Yale University School of Medicine. He is also a director for the Yale Center for Interdisciplinary Research on AIDS. His primary research interests are mortality and morbidity in relation to injection drug use and HIV transmission. Dr. Heimer’s research provides health and prevention practitioners with information by examining consequences of drug abuse in the United States and Russia. He is the principal investigator for Yale Emerging Infections Program and for a project titled “Environmental Factors in HIV Transmission about Suburban IDUs.”

Robert Heimer received his M.S. and Ph.D. from Yale University. He is also a member of a Substance Use Working Group. Grants for his international work include: International Feasibility Study of Pharmacy-Based HIV Prevention: St. Petersburg Influences on HIV Prevalence and Service Access among IDU’s in Russia and Estonia.Influences on HIV Prevalence and Service Access among IDUs in Russia and Estonia (REGIMES)
We are studying the impacts of ethnicity and stigma on HIV prevalence and on access to HIV prevention and care services in St. Petersburg and Kohtla-Järve.
1 R01 DA029888-01 (Heimer/Uuskula)
09/01/2010– 07/31/2015

Environmental Factors in HIV Transmission among Suburban IDUs (SHERPA)

Recent evidence suggests that injection drug use is increasing among suburban residents. Little research has focused on this trend, and the economic, social, and medical consequences have not been considered. To close this gap, we are proposing to identify, recruit, and study a valid sample of injectors who reside in Connecticut suburbs using respondent driven sampling (RDS).
5 R01 DA023408-04 (Heimer)
07/01/2007– 04/30/2012

Drug Policy, Incarceration, Community Re-entry, and Race Disparities in HIV/AIDS (SHARRPP)
The project analyzes the interconnections among drug policies in the US, the massive migration in and out of the criminal justice (CJ) system that these policies have created, and race disparities in HIV risk.
7 R01 DA025021-02 (Blankenship)
09/15/2009– 07/31/2014

Online Respondent-Driven Sampling & Data Collection for Men Who Have Sex with Men
The study assesses the feasibility of improving representativeness of samples of MSM recruited online, a population at acute risk for sexually transmitted infections.
1 R21 MH090920-01A1 (White)
01/01/2011– 12/31/2012

Connecticut Emerging Infections Program (CT-EIP)
The Yale Emerging Infections Program, in partnership with the State of Connecticut Department of Public Health is responsible for carrying out surveillance for emerging and re-emerging infections of particular interest to the CDC, most notably foodborne, respiratory, hepatitis, lyme disease, and other infectious disease.
2009-0238 (Heimer)
12/30/2008– 12/29/2011

International Feasibility Study of Pharmacy-Based HIV Prevention: St. Petersburg
The study assesses the feasibility of using pharmacies as public health venues to provide HIV-prevention to injection drug users (IDUs) in St. Petersburg, Russia. This application is one of the linked R21 proposals developed by India,Vietnam, Russia and USA in preparation for a large-scale, multi-site randomized controlled intervention trial. The expected results of these studies will help to develop the training for the pharmacists to provide HIV- related services to IDUs as highly effective intervention that could be implemented in a wide variety of cultural settings.
5 R21 DA027228-02 (Shaboltas)
09/15/2009– 08/31/2012

Alcohol and HIV Risk Reduction in St. Petersburg, Russian Federation
We are developing and testing a theory-based risk reduction intervention for men and women who drink alcohol, who are seeking VCT at STI clinics and are at risk for contracting and transmitting HIV in St. Petersburg, Russia.
5 R01 AA17389-04 (Abdala)
09/30/2007– 06/30/2011

Center for Public Health Excellence in HIV Prevention in the Russian Federation
The primary aim of the projects are (1) setting up a scientific and methodological center for research and development to facilitate efficiency improvement of organizations engaged in HIV control and prevention in the Russian Federation, (2) analyzing previously collected biobehavioral and surveillance data, (3)conducting studies on HIV prevalence in IDU and bridge populations in two Russian cities, and (4) developing manuals and courses to teach research methods on these topics.
CRDF 47.079 (Levina and Heimer)
6/15/2008- 3/31/2011
Civilian Research & Development Foundation

Monitoring and Evaluation of Program to Promote Youth Friendly Sexual and Reproductive Health Services in 8 CIS Nations
The primary aims of this project are to provide the implementers of the program with the reporting tools to determine the impact of their efforts and to analyze the reports to inform the project funder (the government of Finland) of project accomplishments and failures.
UREC6R52A Heimer (PI)
07/01/09– 07/31/11

Training and Research in HIV Prevention in Russia
This training grant continues to develop a cadre of researchers at four institutions in St. Petersburg thereby building capacity in Russian institutions to address their expanding HIV/AIDS epidemic.
5D43TW001028-10 (Heimer)
09/30/98– 05/31/16
Fogarty International Center

Center for Interdisciplinary Research on AIDS (CIRA)
Conduct research aimed at the prevention of HIV infection and reduction of the negative consequences of HIV disease in vulnerable and underserved populations. Through multidisciplinary collaborations, such research will identify determinants of risky behaviors, evaluate interventions in local, high-risk populations,develop and test models to assess the impact of these interventions on the epidemic, and determine transferability of specific intervention approaches between the United States and selected developing countries.
5 P30 MH062294-08 (Cleary)
09/30/2008– 06/30/2013

Assessing Epidemiological Risks of Parenteral HCV Transmission in Drug Users
This project has been designed to understand the risks for transmission of the hepatitis C virus (HCV) through unsafe drug injection and evaluate methods to reduce transmission. The study protocol fuses into laboratory-based research the real-world observations on drug injection practices to analyze (1) the potential for HCV transmission resulting from the use of HCV-contaminated injection equipment, (2) the duration of HCV viability in injection equipment, (3) the potential for disinfectants to inactivate HCV, and (4) the potential for exposure to infectious HCV in various drug preparation and injection practices common in parts of the world where the HCV epidemic among injection drugs users is still rapidly increasing.
R01 DA030420-A101 (Heimer)
07/01/2011 – 06/30/2016

Selected Publications

Edit this profile

Contact Info

Robert Heimer, PhD
Office Location
Laboratory of Epidemiology and Public Health
60 College Street, Ste Suite 504

New Haven, CT 06510
View on map...
Mailing Address
Yale School of Public HealthPO Box 208034
60 College Street

New Haven, CT 06520-8034

Curriculum Vitae